Journey Medical Corporation (DERM) Actualités

Form PRE 14A - Other preliminary proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey...

Form 8-K - Current report

Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial...

Form 8-K - Current report

Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz...

Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the...

Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended...